Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
Trial ID or NCT#
NCT00892931
Status
NOT RECRUITING
Purpose
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
Official Title
Phase 2 Study of Azixa (MPC-6827) for the Treatment of Patients With Recurrent Glioblastoma Multiforme
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- * Have histologically proven malignant Glioblastoma Multiforme in first or second relapse* Have failed prior Fractionated External Beam Cranial Irradiation or IMRT* Be at least 18 years old and with a life expectancy ≥ 8 weeks or ≥ 4 weeks if failed prior Avastin therapy* Have a Karnofsky performance status of ≥ 60* Have adequate bone marrow function, liver function, and renal function before starting therapy
Exclusion Criteria:
- * Have had more than two relapses* Have had radiosurgery* Have a cardiac ejection fraction \< 50% by MUGA or ECHO* Have Troponin-I elevated above the normal range* Have an increasing steroid requirement* Have MRI evidence at baseline of enlarging or clinically significant intratumor hemorrhage* Have active stroke and/or transient ischemic attack not optimally managed* Have active cardiovascular disease (e.g. sub-optimally managed angina, impending myocardial infarction, or uncontrolled hypertension)* Be pregnant or breast feeding* Have had prior hypersensitivity reaction to Cremophor EL* Be HIV positive
Investigator(s)
Lawrence Recht, MD
Neuro-oncologist
Professor of Neurology and Neurological Sciences (Adult Neurology) and, by courtesy, of Neurosurgery
Contact us to find out if this trial is right for you.
Contact
Cancer Clinical Trials Office
650-498-7061
View on ClinicalTrials.gov
